参麦注射液联合甲磺酸加贝酯治疗急性胰腺炎的疗效观察

目的探究参麦注射液联合甲磺酸加贝酯治疗急性胰腺炎的临床疗效。方法选取2014年1月—2016年7月重庆市巴南区第二人民医院收治的急性胰腺炎患者96例,随机分为对照组和治疗组,每组各48例。对照组在常规治疗的基础上静脉滴注注射用甲磺酸加贝酯,前3 d 300 mg/d,3 d后100 mg/d。治疗组患者在对照组的基础上静脉滴注参麦注射液40 m L/d,两组均治疗2周。观察两组的临床疗效,比较两组的临床症状改善及住院时间和血淀粉酶、尿淀粉酶、血白细胞(WBC)和血门冬氨酸氨基转移酶(AST)及其不良反应情况。结果治疗后,对照组和治疗组的总有效率分别为79.41%、91.67%,两组比较差异具有统计学意义(P0.05)。治疗后,治疗组的腹痛缓解时间、腹部压痛消失时间、住院时间和血淀粉酶恢复正常时间均短于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者的血淀粉酶、尿淀粉酶、血WBC和血AST均较治疗前显著降低,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组患者的上述观察指标均明显低于对照组,两组比较差异具有统计学意义(P0.05)。两组不良反应发生情况比较差异无统计学意义。结论参麦注射液联合甲磺酸加贝酯治疗急性胰腺炎的疗效显著,安全性较高,具有一定的临床推广应用价值。

Clinical observation of Shenmai Injection combined with gabexate mesilate in treatment of acute pancreatitis

Objective To explore the curative effect of Shenmai Injection combined with gabexate mesilate in treatment of acute pancreatitis. Methods Patients (96 cases) with acute pancreatitis in the Second People''s Hospital of Banan District in Chongqing from January 2014 to July 2016 were randomly divided into control and treatment groups, and each group had 48 cases. Patients in the control group were iv administered with Gabexate Mesilate for injection on the basis of conventional therapy, 300 mg/d on the three days before administration, and after three days the dosage was adjusted to 100 mg/d. Patients in the treatment group were iv administered with Shenmai Injection on the basis of the control group, 40 mL/d. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and the time of clinical symptoms improvement and hospitalization, blood amylase, urine amylase, WBC, AST, and adverse reactions in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 79.41% and 91.67%, respectively, and there was difference between two groups (P < 0.05). After treatment, remission time of abdominal pain, the disappearance time of abdominal tenderness, hospitalization time, and the time of blood amylase returned to normal was shorter than those in the control group, and there was difference between two groups (P < 0.05). After treatment, blood amylase, urine amylase, WBC, and AST in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these observed indicators in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). There was no significant difference in adverse reactions between two groups. Conclusion Shenmai Injection combined with gabexate mesilate has clinical curative effect in treatment of acute pancreatitis with high safety, which has a certain clinical application value.